Rallybio Corp (RLYB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$15.69-1.32%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RLYB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 0.9 | 0.6 | — | — | — | — |
| Total Revenues | — | 0.9 | 0.6 | — | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 7.9 | 19.6 | 41.5 | 53.5 | 40.7 | 26.9 | 17.6 |
| Operating Income | (24.2) | (33.1) | (60.5) | (78.9) | (67.9) | (45.6) | (25.3) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | — | — | — | 0.0 | 0.0 | 0.0 |
| Other Non-Operating Income / Expenses | 52.4 | 25.0 | 5.0 | 6.4 | 2.3 | 0.1 | 0.4 |
| EBT, Incl. Unusual Items | 28.2 | (8.1) | (55.5) | (72.5) | (65.6) | (45.5) | (24.9) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | (0.0) |
| Net Income | |||||||
| Net Income | 26.8 | (9.0) | (57.8) | (74.6) | (66.7) | (47.0) | (26.4) |
| Per Share | |||||||
| Basic EPS | 4.69 | (1.59) | (1.33) | (1.84) | (2.09) | (1.84) | — |
| Diluted EPS | 4.69 | (1.59) | (1.33) | (1.84) | (2.09) | (1.84) | — |
| Basic Weighted Avg Shares | 5.7 | 5.6 | 43.5 | 40.4 | 31.8 | 25.5 | — |
| Diluted Weighted Avg Shares | 5.7 | 5.6 | 43.5 | 40.4 | 31.8 | 25.5 | — |
| Supplemental | |||||||
| EBITDA | — | (33.0) | (60.4) | (78.8) | (67.7) | (45.5) | (25.2) |
| EBIT | (24.2) | (33.1) | (60.5) | (78.9) | (67.9) | (45.6) | (25.3) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | 0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.